2024-09-10 - Analysis Report
## PM Stock Analysis Report

**Company Overview:** PM is a leading pharmaceutical company known for its diverse product portfolio and global presence.

**Performance Summary:**

* **Relative Performance:** PM's cumulative return of 63.55% lags behind the S&P 500 (VOO) return of 81.34%. This represents a 17.79% difference, which is currently at the 50.69th percentile compared to historical performance data.
* **Price Movement:** The current price of PM is $125.81. The stock is currently trading above its 5-day, 20-day, and 60-day moving averages, indicating potential upward momentum. 
* **Technical Indicators:** The RSI of 86.38 indicates the stock is currently in overbought territory, suggesting potential for a correction. The PPO value of 0.1 suggests moderate bullish momentum. The 20-day relative divergence indicates a recent increase in momentum, with a 11.4% jump.
* **Expected Return:** The expected return for PM is 10.98% over the next five years, based on current investment amount.
* **Recent Earnings:** PM's recent earnings have been consistent and show a trend of growth.  The most recent earnings report for Q2 2024 revealed an EPS of $1.54, exceeding the consensus estimate of $1.35, and revenue of $9.47 billion, surpassing the expected $9.20 billion. The company's recent performance suggests a strong financial foundation and potential for continued growth. 

**Overall Analysis:**

PM has demonstrated consistent earnings growth and a strong financial position. However, the stock's recent price movement and overbought technical indicators suggest a potential for short-term correction.  Despite underperforming the S&P 500 in the long term, the positive outlook on earnings and potential for future growth make PM an interesting investment opportunity with a potential return of 10.98% over the next 5 years. Investors should closely monitor the stock's price movement and technical indicators for potential entry and exit points. 
